88. 慢性血栓塞栓性肺高血圧症 Chronic thromboembolic pulmonary hypertension Clinical trials / Disease details
臨床試験数 : 157 / 薬物数 : 107 - (DrugBank : 22) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 54
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-163279 | 10/6/2016 | 01/06/2016 | A confirmatory (phase III) study of the efficacy and safety of NS-304 (selexipag) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) | A confirmatory (phase III) study of the efficacy and safety of NS-304 (selexipag) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) | Chronic thromboembolic pulmonary hypertension (CTEPH) | Intervention name : NS-304 INN of the intervention : Selexipag Dosage And administration of the intervention : Oral administration Control intervention name : NS-304 Placebo INN of the control intervention : - Dosage And administration of the control intervention : Oral administration | Nippon Shinyaku Co., Ltd. | NULL | complete | 20 | 85 | BOTH | 72 | Phase 3 | Japan |
| 2 | JPRN-JapicCTI-132159 | 01/5/2013 | 13/06/2013 | NS-304 CTEPH OE | The open-label extension study of NS-304 in patients with chronic thromboembolic pulmonary hypertension (CTEPH) | Chronic thromboembolic pulmonary hypertension (CTEPH) | Intervention name : NS-304 INN of the intervention : Selexipag Dosage And administration of the intervention : Oral administration | NIPPON SHINYAKU CO., LTD. | NULL | BOTH | 2 | Phase 2 | NULL | |||
| 3 | JPRN-JapicCTI-111666 | 01/6/2010 | 18/10/2011 | NS-304 CTEPH OL study | The open-label extension study of NS-304 in patients with chronic thromboembolic pulmonary hypertension (CTEPH) who completed the exploratory evaluation study | Chronic thromboembolic pulmonary hypertension (CTEPH) | Intervention name : NS-304 INN of the intervention : Selexipag Dosage And administration of the intervention : Oral administration | NIPPON SHINYAKU CO., LTD. / Actelion Pharmaceuticals Japan Ltd. | NULL | BOTH | 32 | Phase 2 | NULL | |||
| 4 | JPRN-JapicCTI-111667 | 01/2/2010 | 18/10/2011 | NS-304 CTEPH DB study | An exploratory study to assess the efficacy and safety of NS-304 in patients with chronic thromboembolic pulmonary hypertension (CTEPH) | Chronic thromboembolic pulmonary hypertension (CTEPH) | Intervention name : NS-304 INN of the intervention : Selexipag Dosage And administration of the intervention : Oral administration Control intervention name : Placebo Dosage And administration of the control intervention : Oral administration | NIPPON SHINYAKU CO., LTD. / Actelion Pharmaceuticals Japan Ltd. | NULL | 20 | 75 | BOTH | 32 | Phase 2 | NULL |